ELISA News and Research

RSS

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

Researchers in the UK have provided evidence that Pfizer-BioNTech’s coronavirus disease 2019 (COVID-19) vaccine induces effective immune responses in patients with myeloproliferative neoplasms.

13 May 2021

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

A team of scientists from the Washington University School of Medicine and the University of Texas Medical Branch, USA, has recently evaluated the durability and robustness of an adenovirus-vectored, spike-based intranasal COVID-19 vaccine in mice.

11 May 2021

3D printing technique extends the possibilities of lateral flow tests

Researchers at KU Leuven (Belgium) have developed a 3D printing technique that extends the possibilities of lateral flow testing.

10 May 2021

Researchers study how cancer cells re-organize 3D structure of DNA to ramp up oncogene activity

In cancer, a lot of biology goes awry: Genes mutate, molecular processes change dramatically, and cells proliferate uncontrollably to form entirely new tissues that we call tumors.

10 May 2021

New nanoimmunoassay can detect anti–SARS-CoV-2 antibodies in ultralow-volume blood samples

In a recent study, researchers developed and validated a nanoimmunoassay (NIA) that analyzes 1,024 samples in parallel on a single microfluidic device the size of a USB stick. They detected anti-SARS-CoV-2 IgG antibodies, achieving a sensitivity of 98% and specificity of 100% based on an analysis of 134 pre-pandemic sera (collected in 2013/2014 and 2018) and 155 sera from reverse transcription-polymerase chain reaction (RT-PCR) positive individuals.

10 May 2021

Prevalence of SARS-CoV-2 antibodies in Germany

Seroprevalence studies have proved their worth in estimating the size and directionality of an outbreak of infectious disease, especially the current pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-induced coronavirus disease 2019 (COVID-19). A new study posted to the medRxiv* preprint server describes the prevalence of SARS-CoV-2 antibodies in five representative regions of Germany.

10 May 2021

Large-scale study focuses on COVID-19 antibodies in asymptomatic and symptomatic patients

MUSC Hollings Cancer Center researchers added to the understanding of the protective immune response against the SARS-CoV-2 virus in a study published in April in iScience.

6 May 2021

Guidance on diagnosis and management of cerebral venous sinus thrombosis after a COVID-19 vaccine

Last Friday, the Centers for Disease Control and Prevention and the U.S. Food & Drug Administration lifted the pause in administration of the Johnson & Johnson (Janssen) COVID-19 vaccine in the U.S.

29 Apr 2021

Study examines smoking behavior after the implementation of California law

Smoking is the leading cause of preventable death in America and causes about 30% of all cancer deaths. That's why researchers with the UC Davis Comprehensive Cancer Center wanted to study the impact of a California law passed in 2016 that raised the tobacco sales age from 18 to 21.

26 Apr 2021

Researchers conduct a SARS-CoV-2 serosurvey of blood donors in New Zealand

New research has been released, which focuses on the transmission and prevalence of SARS-CoV-2 in New Zealand, through a blood donor serosurvey.

22 Apr 2021

SARS-CoV-2 vaccine with single-cycle adenovirus vector

Researchers in the United States have developed adenovirus vectors that may be more effective at generating immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) than those used in the vaccines that are currently being rolled out to help combat the coronavirus disease 2019 (COVID-19) pandemic.

21 Apr 2021

SARS-CoV-2-associated ssRNAs trigger inflammation and immunity via toll-like receptors

Severe COVID-19 causes sepsis-like manifestations, intense lung injury, and multi-organ failure, all associated with the overproduction of pro-inflammatory cytokines. This "cytokine storm" directly correlates with poor prognosis in this subgroup of patients.

21 Apr 2021

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Researchers in the United States have shown that an antibody test measuring host reactivity to the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may better detect natural infection among vaccinated individuals than an assay that measures reactivity to the viral spike protein.

21 Apr 2021

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

To monitor antibody level duration of vaccine-induced immune responses, a team of researchers in the U.S. – at Diacarta, University of California and VA Healthcare System, and the Franciscan University of Steubenville – evaluated the feasibility of using a single drop of fingerstick blood collected with flocked swabs for quantitative antibody response evaluation after COVID-19 vaccination.

20 Apr 2021

Researchers reveal long-term kinetics of anti-SARS-CoV-2 antibodies in patient sera

A team of scientists in Germany recently evaluated the specificities and sensitivities of different serological assays for detecting antibodies against SARS-CoV-2.

19 Apr 2021

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Researchers in the United States have developed an alternative messenger RNA (mRNA) delivery platform to the lipid nanoparticles that are currently used in vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

18 Apr 2021

Past COVID-19 infection does not completely protect against reinfection in young people

Although antibodies induced by SARS-CoV-2 infection are largely protective, they do not completely protect against reinfection in young people, as evidenced through a longitudinal, prospective study of more than 3,000 young, healthy members of the US Marines Corps conducted by researchers at the Icahn School of Medicine at Mount Sinai and the Naval Medical Research Center, published April 15 in The Lancet Respiratory Medicine.

17 Apr 2021

COVID-19 vaccine INO-4800 shows efficacy against SARS-CoV-2 variants

Researchers in the United States have demonstrated the efficacy of the vaccine INO-4800 against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

15 Apr 2021

SARS-CoV-2 spike E484K mutation reduces antibody neutralization

Researchers at the Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, USA, showed that the SARS-CoV-2 spike E484K mutation reduces antibody neutralization.

12 Apr 2021

Autoantibodies may contribute to severe COVID-19 and potential long-COVID-19 symptoms

New research in the USA and China. investigated how autoantibodies could mediate NETs during a COVID-19 infection. Extensive damage to the body from neutrophil extracellular traps (NETs) after infection may be contributing to thromboinflammation and the symptoms experienced by COVID-19 ‘long-haulers’.

8 Apr 2021

ELISA News and Research

Pfizer-BioNTech COVID-19 vaccine effective in patients with myeloproliferative neoplasms

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

3D printing technique extends the possibilities of lateral flow tests

Researchers study how cancer cells re-organize 3D structure of DNA to ramp up oncogene activity

New nanoimmunoassay can detect anti–SARS-CoV-2 antibodies in ultralow-volume blood samples

Prevalence of SARS-CoV-2 antibodies in Germany

Large-scale study focuses on COVID-19 antibodies in asymptomatic and symptomatic patients

Guidance on diagnosis and management of cerebral venous sinus thrombosis after a COVID-19 vaccine

Study examines smoking behavior after the implementation of California law

Researchers conduct a SARS-CoV-2 serosurvey of blood donors in New Zealand

SARS-CoV-2 vaccine with single-cycle adenovirus vector

SARS-CoV-2-associated ssRNAs trigger inflammation and immunity via toll-like receptors

Seroprevalence studies monitoring SARS-CoV-2 among vaccinees require more than spike assays

Can fingerprick blood tests help evaluate antibody response and longevity against SARS-CoV-2 post-vaccination?

Researchers reveal long-term kinetics of anti-SARS-CoV-2 antibodies in patient sera

Novel mRNA delivery vehicle provides alternative to LNPs for SARS-CoV-2 vaccines

Past COVID-19 infection does not completely protect against reinfection in young people

COVID-19 vaccine INO-4800 shows efficacy against SARS-CoV-2 variants

SARS-CoV-2 spike E484K mutation reduces antibody neutralization

Autoantibodies may contribute to severe COVID-19 and potential long-COVID-19 symptoms

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News